Celltrion says U.S. prescriptions for autoimmune drug Steqeyma are expanding
Translated from Korean and summarized by DistantNews. Read the original for the full story.
At a glance
News
Documents & data
Ongoing story
- Celltrion said Steqeyma’s share of the U.S. market rose from 10.2% in February to 16.2% in July.
- Steqeyma is Celltrion’s biosimilar version of Janssen’s autoimmune treatment Stelara.
- Celltrion has sold Steqeyma directly in the United States since last year and is expanding prescriptions.
Celltrion said prescriptions for its autoimmune disease treatment Steqeyma are increasing in the United States.
Data from pharmaceutical market researcher IQVIA showed the drug’s U.S. market share rising from 10.2% in February to 16.2% in July, a gain of 6 percentage points.
Steqeyma is a biosimilar of Stelara, a treatment developed by global pharmaceutical company Janssen. Celltrion has marketed Steqeyma directly in the United States since last year.
About this summary
Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized automatically by DistantNews, with a note on how the source frames the story. Not individually reviewed before publishing. How this works.
More Stories
From Our Blog
What Gets Lost (and Found) When News Is Translated
The Critical Role of Diaspora Media in Global News
What Travellers Should Know About Countries with Restricted Press
A Digital Nomad's Guide to Following Local News
How the Same Story Looks Different in Different Countries
